Literature DB >> 22759592

Emerging frontiers in pancreatic cancer research: elaboration of key genes, cells and the extracellular milieu.

Chandan Kumar-Sinha1, Iris Wei, Diane M Simeone.   

Abstract

PURPOSE OF REVIEW: We review recent literature with a view to forge an integrative understanding of the molecular, cellular and extracellular milieu of pancreatic cancer, and discuss them in the context of development of novel, personalized therapeutic options. RECENT
FINDINGS: Pancreatic tumorigenesis, examined using genetically engineered mouse models, appears to be driven by local inflammation, in concert with the 'big four' mutations involving oncogenic KRAS, SMAD4, CDKN2A, and TP53, through induction of epithelial-to-mesenchymal transition (EMT) and cancer stem cells, and accompanied by metastasis. High-throughput sequencing of pancreatic ductal adenocarcinoma as well as neuroendocrine tumors and rarer subtypes of cancers of the pancreas has revealed several novel mutations in genes like PALB2, guanine nucleotide-binding protein, alpha stimulating, death-domain-associated protein, α thalassemia/mental retardation syndrome X linked, switch/sucrose nonfermentable pathway related, and in genes in the ubiquitin-dependent pathways such as USP9X. Therapeutic targeting of the tumor-stroma axis by cytokines and immune response modulators and the role of autophagy in pancreatic cancer are some other salient themes explored in the recent publications.
SUMMARY: Recent publications shed new light on the mutational landscape of pancreatic cancer and further delineate the distinctive pancreatic cancer-stroma ecosystem as determined by the dynamic interplay of inflammation, hallmark mutations, EMT, and cancer stem cells.

Entities:  

Mesh:

Year:  2012        PMID: 22759592      PMCID: PMC3680108          DOI: 10.1097/MOG.0b013e3283567f69

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  59 in total

1.  Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.

Authors:  Shinichi Yachida; Efsevia Vakiani; Catherine M White; Yi Zhong; Tyler Saunders; Richard Morgan; Roeland F de Wilde; Anirban Maitra; Jessica Hicks; Angelo M Demarzo; Chanjuan Shi; Rajni Sharma; Daniel Laheru; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Ralph H Hruban; Laura H Tang; David S Klimstra; Christine A Iacobuzio-Donahue
Journal:  Am J Surg Pathol       Date:  2012-02       Impact factor: 6.394

2.  An in vivo platform for translational drug development in pancreatic cancer.

Authors:  Belen Rubio-Viqueira; Antonio Jimeno; George Cusatis; Xianfeng Zhang; Christine Iacobuzio-Donahue; Collins Karikari; Chanjusn Shi; Kathleen Danenberg; Peter V Danenberg; Hidekazu Kuramochi; Koji Tanaka; Sharat Singh; Hossein Salimi-Moosavi; Nadia Bouraoud; Maria L Amador; Soner Altiok; Piotr Kulesza; Charles Yeo; Wells Messersmith; James Eshleman; Ralph H Hruban; Anirban Maitra; Manuel Hidalgo
Journal:  Clin Cancer Res       Date:  2006-08-01       Impact factor: 12.531

3.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer.

Authors:  Peter J Campbell; Shinichi Yachida; Laura J Mudie; Philip J Stephens; Erin D Pleasance; Lucy A Stebbings; Laura A Morsberger; Calli Latimer; Stuart McLaren; Meng-Lay Lin; David J McBride; Ignacio Varela; Serena A Nik-Zainal; Catherine Leroy; Mingming Jia; Andrew Menzies; Adam P Butler; Jon W Teague; Constance A Griffin; John Burton; Harold Swerdlow; Michael A Quail; Michael R Stratton; Christine Iacobuzio-Donahue; P Andrew Futreal
Journal:  Nature       Date:  2010-10-28       Impact factor: 49.962

4.  Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.

Authors:  Maria C Villarroel; N V Rajeshkumar; Ignacio Garrido-Laguna; Ana De Jesus-Acosta; Siân Jones; Anirban Maitra; Ralph H Hruban; James R Eshleman; Alison Klein; Daniel Laheru; Ross Donehower; Manuel Hidalgo
Journal:  Mol Cancer Ther       Date:  2010-12-06       Impact factor: 6.261

5.  Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development.

Authors:  Jian Wu; Hanno Matthaei; Anirban Maitra; Marco Dal Molin; Laura D Wood; James R Eshleman; Michael Goggins; Marcia I Canto; Richard D Schulick; Barish H Edil; Christopher L Wolfgang; Alison P Klein; Luis A Diaz; Peter J Allen; C Max Schmidt; Kenneth W Kinzler; Nickolas Papadopoulos; Ralph H Hruban; Bert Vogelstein
Journal:  Sci Transl Med       Date:  2011-07-20       Impact factor: 17.956

6.  A comprehensive catalogue of somatic mutations from a human cancer genome.

Authors:  Erin D Pleasance; R Keira Cheetham; Philip J Stephens; David J McBride; Sean J Humphray; Chris D Greenman; Ignacio Varela; Meng-Lay Lin; Gonzalo R Ordóñez; Graham R Bignell; Kai Ye; Julie Alipaz; Markus J Bauer; David Beare; Adam Butler; Richard J Carter; Lina Chen; Anthony J Cox; Sarah Edkins; Paula I Kokko-Gonzales; Niall A Gormley; Russell J Grocock; Christian D Haudenschild; Matthew M Hims; Terena James; Mingming Jia; Zoya Kingsbury; Catherine Leroy; John Marshall; Andrew Menzies; Laura J Mudie; Zemin Ning; Tom Royce; Ole B Schulz-Trieglaff; Anastassia Spiridou; Lucy A Stebbings; Lukasz Szajkowski; Jon Teague; David Williamson; Lynda Chin; Mark T Ross; Peter J Campbell; David R Bentley; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2009-12-16       Impact factor: 49.962

7.  Activating mutation of the stimulatory G protein (gsp) as a putative cause of ovarian and testicular human stromal Leydig cell tumors.

Authors:  M C Fragoso; A C Latronico; F M Carvalho; M C Zerbini; J A Marcondes; L M Araujo; V S Lando; E T Frazzatto; B B Mendonca; S M Villares
Journal:  J Clin Endocrinol Metab       Date:  1998-06       Impact factor: 5.958

Review 8.  The cancer genome.

Authors:  Michael R Stratton; Peter J Campbell; P Andrew Futreal
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

9.  Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy.

Authors:  Enza Lonardo; Patrick C Hermann; Maria-Theresa Mueller; Stephan Huber; Anamaria Balic; Irene Miranda-Lorenzo; Sladjana Zagorac; Sonia Alcala; Iker Rodriguez-Arabaolaza; Juan Carlos Ramirez; Raul Torres-Ruíz; Elena Garcia; Manuel Hidalgo; David Álvaro Cebrián; Rainer Heuchel; Matthias Löhr; Frank Berger; Peter Bartenstein; Alexandra Aicher; Christopher Heeschen
Journal:  Cell Stem Cell       Date:  2011-11-04       Impact factor: 24.633

10.  The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma.

Authors:  Pedro A Pérez-Mancera; Alistair G Rust; Louise van der Weyden; Glen Kristiansen; Allen Li; Aaron L Sarver; Kevin A T Silverstein; Robert Grützmann; Daniela Aust; Petra Rümmele; Thomas Knösel; Colin Herd; Derek L Stemple; Ross Kettleborough; Jacqueline A Brosnan; Ang Li; Richard Morgan; Spencer Knight; Jun Yu; Shane Stegeman; Lara S Collier; Jelle J ten Hoeve; Jeroen de Ridder; Alison P Klein; Michael Goggins; Ralph H Hruban; David K Chang; Andrew V Biankin; Sean M Grimmond; Lodewyk F A Wessels; Stephen A Wood; Christine A Iacobuzio-Donahue; Christian Pilarsky; David A Largaespada; David J Adams; David A Tuveson
Journal:  Nature       Date:  2012-04-29       Impact factor: 49.962

View more
  7 in total

Review 1.  Embryonic stem cell factors and pancreatic cancer.

Authors:  Marta Herreros-Villanueva; Luis Bujanda; Daniel D Billadeau; Jin-San Zhang
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

2.  Oncogenic miR-23a in Pancreatic Ductal Adenocarcinogenesis Via Inhibiting APAF1.

Authors:  Ning Liu; Yuan-Yuan Sun; Xiao-Wen Zhang; Sheng Chen; Ye Wang; Zhao-Xiong Zhang; Shao-Wei Song; Guang-Bin Qiu; Wei-Neng Fu
Journal:  Dig Dis Sci       Date:  2015-02-21       Impact factor: 3.199

3.  Effect of NR5A2 inhibition on pancreatic cancer stem cell (CSC) properties and epithelial-mesenchymal transition (EMT) markers.

Authors:  Zhaofan Luo; Yanan Li; Mingxin Zuo; Chang Liu; Weihua Tian; Dong Yan; Huamin Wang; Donghui Li
Journal:  Mol Carcinog       Date:  2017-01-12       Impact factor: 4.784

4.  Netrin-1 promoted pancreatic cancer cell proliferation by upregulation of Mdm2.

Authors:  Qian Huang; Hong-Wei Hua; Feng Jiang; Dai-He Liu; Gang Ding
Journal:  Tumour Biol       Date:  2014-07-08

5.  Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.

Authors:  Eva J ter Weele; Anton G T Terwisscha van Scheltinga; Jos G W Kosterink; Linda Pot; Silke R Vedelaar; Laetitia E Lamberts; Simon P Williams; Marjolijn N Lub-de Hooge; Elisabeth G E de Vries
Journal:  Oncotarget       Date:  2015-12-08

6.  ITGA1 is a pre-malignant biomarker that promotes therapy resistance and metastatic potential in pancreatic cancer.

Authors:  Armen Gharibi; Sa La Kim; Justin Molnar; Daniel Brambilla; Yvess Adamian; Malachia Hoover; Julie Hong; Joy Lin; Laurelin Wolfenden; Jonathan A Kelber
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

7.  LRH1 as a promising prognostic biomarker and predictor of metastasis in patients with non-small cell lung cancer.

Authors:  Yuechao Liu; Ying Xing; Hongmei Wang; Shi Yan; Xinzhu Wang; Li Cai
Journal:  Thorac Cancer       Date:  2018-10-01       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.